USA: Results from the pivotal STORM-PE randomized controlled trial, presented as a Late-Breaking Clinical Trial at TCT 2025, have provided the first head-to-head evidence comparing mechanical thrombectomy (MT) combined with anticoagulation (AC) against anticoagulation alone in patients with acute intermediate-high-risk pulmonary embolism (PE) . The findings highlight that computer-assisted vacuum thrombectomy (CAVT) offers meaningful improvements in right-heart function while maintaining a strong safety profile, marking a major advancement in the treatment of this serious condition. Pulmonary embolism remains a major cause of cardiovascular mortality. While anticoagulation is the standard treatment, patients with intermediate-high-risk PE—characterized by right ventricular dysfun

See Full Page